Scilex Holding (SCLX) Registration filing summary

Company overview and business model

• Focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain indications, targeting high unmet needs and large market opportunities.

• Commercial portfolio includes ZTlido® (lidocaine topical system), ELYXYB® (oral solution for migraine), and GLOPERBA® (liquid colchicine for gout), with additional late-stage product candidates in development.

• Employs a patient-first approach, leveraging research and development to address global demand for safer, more effective pain relief solutions.

• Holds exclusive worldwide rights (except Japan) to ZTlido’s proprietary formulation and manufacturing technologies.

Financial performance and metrics

• Identified as an emerging growth company under the JOBS Act, utilizing certain reduced public company reporting requirements.

• Audited financial statements for the year ended December 31, 2023, include a going concern explanatory paragraph.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling securityholders; will receive up to $4.2 million from the exercise of Financing Warrants if exercised for cash.

• Proceeds from warrant exercises are intended for working capital and general corporate purposes, including capital expenditures, commercialization, R&D, regulatory affairs, clinical trials, acquisitions, and debt repayment.

• No specific uses or amounts designated; retains broad discretion over allocation.